Volume 90 Issue 5 | p. 9 | News of The Week
Issue Date: January 30, 2012

Amgen And Celgene Acquire Cancer Drug Companies

Department: Business
Keywords: biotechnology, M&A, cancer, antibodies, covalent drugs

Amgen and Celgene are each launching into 2012 with acquisitions that beef up their cancer drug pipelines and add unique technologies.

Amgen will pay $1.2 billion for Micro­met, which brings bispecific T-cell engager (BiTE) antibody technology. BiTE antibodies bind to both tumor cells and T cells, causing cancer cell death and proliferation of more T cells at the tumor site. Amgen also gets blinatumomab, a BiTE antibody in Phase . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society